Target type: biologicalprocess
Any process that activates or increases the frequency, rate or extent of sodium ion export across the plasma membrane. [GO_REF:0000058, GOC:BHF, GOC:rl, GOC:TermGenie, PMID:17095720]
Positive regulation of sodium ion export across the plasma membrane is a complex process essential for maintaining cellular homeostasis and regulating various physiological functions. It involves a coordinated interplay of various proteins and mechanisms that ensure the efficient removal of sodium ions from the cell.
**Key Players:**
1. **Sodium-Potassium Pump (Na+/K+ ATPase):** This transmembrane protein is the primary driver of sodium export. It utilizes energy from ATP hydrolysis to pump three sodium ions out of the cell and two potassium ions into the cell, creating an electrochemical gradient for sodium.
2. **Sodium-Hydrogen Exchanger (NHE):** This protein exchanges intracellular hydrogen ions for extracellular sodium ions. This mechanism is particularly important in regulating intracellular pH and can contribute to sodium export.
3. **Sodium-Bicarbonate Cotransporter (NBC):** This transporter moves sodium ions and bicarbonate ions together across the membrane. It plays a role in bicarbonate transport and can influence sodium export.
4. **Sodium-Calcium Exchanger (NCX):** This protein exchanges sodium ions for calcium ions. It can contribute to sodium export, particularly in cells where calcium levels need to be regulated.
5. **Sodium Channels:** While not directly involved in active export, these channels can passively allow sodium ions to move out of the cell, influenced by the electrochemical gradient established by other pumps.
**Regulation:**
The activity of these transporters is regulated by various factors:
1. **Hormones:** Aldosterone, a hormone produced by the adrenal glands, stimulates sodium reabsorption in the kidney, indirectly contributing to sodium export in other cells.
2. **Intracellular pH:** Changes in intracellular pH can affect the activity of NHE, influencing sodium export.
3. **Calcium levels:** Increased intracellular calcium can activate NCX, leading to increased sodium export.
4. **Phosphorylation:** Phosphorylation of specific proteins can modulate the activity of pumps and exchangers, regulating sodium export.
**Consequences of Dysregulation:**
Dysregulation of sodium export can lead to various health problems, including:
1. **Edema:** Excess sodium retention can lead to fluid accumulation in tissues, causing swelling.
2. **Hypertension:** Increased sodium levels in the blood can contribute to high blood pressure.
3. **Cardiovascular disease:** Disruptions in sodium balance can impact heart function and contribute to heart failure.
4. **Kidney disease:** Impaired sodium regulation can lead to kidney dysfunction and damage.
**Conclusion:**
Positive regulation of sodium ion export across the plasma membrane is a vital cellular process that ensures proper electrolyte balance, intracellular pH control, and overall physiological function. The intricate network of proteins and mechanisms involved in this process highlights its complexity and significance for maintaining health and well-being.'
"
| Protein | Definition | Taxonomy |
|---|---|---|
| Sodium/potassium-transporting ATPase subunit beta-3 | A sodium/potassium-transporting ATPase subunit beta-3 that is encoded in the genome of human. [PRO:WCB, UniProtKB:P54709] | Homo sapiens (human) |
| Sodium/potassium-transporting ATPase subunit beta-2 | A sodium/potassium-transporting ATPase subunit beta-2 that is encoded in the genome of human. [PRO:DNx, UniProtKB:P14415] | Homo sapiens (human) |
| Sodium/potassium-transporting ATPase subunit beta-1 | A sodium/potassium-transporting ATPase subunit beta-1 that is encoded in the genome of human. [PRO:DNx, UniProtKB:P05026] | Homo sapiens (human) |
| Compound | Definition | Classes | Roles |
|---|---|---|---|
| lansoprazole | Lansoprazole: A 2,2,2-trifluoroethoxypyridyl derivative of timoprazole that is used in the therapy of STOMACH ULCERS and ZOLLINGER-ELLISON SYNDROME. The drug inhibits H(+)-K(+)-EXCHANGING ATPASE which is found in GASTRIC PARIETAL CELLS. Lansoprazole is a racemic mixture of (R)- and (S)-isomers. | benzimidazoles; pyridines; sulfoxide | anti-ulcer drug; EC 3.6.3.10 (H(+)/K(+)-exchanging ATPase) inhibitor |
| omeprazole | 5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole : A member of the class of benzimidazoles that is 1H-benzimidazole which is substituted by a [4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl group at position 2 and a methoxy group at position 5. omeprazole : A racemate comprising equimolar amounts of (R)- and (S)-omeprazole. Omeprazole: A 4-methoxy-3,5-dimethylpyridyl, 5-methoxybenzimidazole derivative of timoprazole that is used in the therapy of STOMACH ULCERS and ZOLLINGER-ELLISON SYNDROME. The drug inhibits an H(+)-K(+)-EXCHANGING ATPASE which is found in GASTRIC PARIETAL CELLS. | aromatic ether; benzimidazoles; pyridines; sulfoxide | |
| pantoprazole | pantoprazole : A member of the class of benzimidazoles that is 1H-benzimidazole substituted by a difluoromethoxy group at position 5 and a [(3,4-dimethoxypyridin-2-yl)methyl]sulfinyl group at position 2. Pantoprazole: 2-pyridinylmethylsulfinylbenzimidazole proton pump inhibitor that is used in the treatment of GASTROESOPHAGEAL REFLUX and PEPTIC ULCER. | aromatic ether; benzimidazoles; organofluorine compound; pyridines; sulfoxide | anti-ulcer drug; EC 3.6.3.10 (H(+)/K(+)-exchanging ATPase) inhibitor; environmental contaminant; xenobiotic |
| digoxigenin | digoxigenin : A hydroxy steroid that consists of 5beta-cardanolide having a double bond at the 20(22)-position as well as hydroxy groups at the 3beta-, 12beta- and 14beta-positions. It has been isolated from the plant species of the genus Digitalis. Digoxigenin: 3 beta,12 beta,14-Trihydroxy-5 beta-card-20(22)-enolide. A cardenolide which is the aglycon of digoxin. Can be obtained by hydrolysis of digoxin or from Digitalis orientalis L. and Digitalis lanata Ehrh. | 12beta-hydroxy steroid; 14beta-hydroxy steroid; 3beta-hydroxy steroid; 3beta-sterol | hapten; plant metabolite |
| digoxigenin-bis(digitoxoside) | cardenolide glycoside | ||
| rostafuroxin | rostafuroxin: structure in first source | ||
| ouabain | cardiac glycoside : Steroid lactones containing sugar residues that act on the contractile force of the cardiac muscles. ouabain : A steroid hormone that is a multi-hydroxylated alpha-L-rhamnosyl cardenoloide. It binds to and inhibits the plasma membrane Na(+)/K(+)-ATPase (sodium pump). It has been isolated naturally from Strophanthus gratus. Ouabain: A cardioactive glycoside consisting of rhamnose and ouabagenin, obtained from the seeds of Strophanthus gratus and other plants of the Apocynaceae; used like DIGITALIS. It is commonly used in cell biological studies as an inhibitor of the NA(+)-K(+)-EXCHANGING ATPASE. | 11alpha-hydroxy steroid; 14beta-hydroxy steroid; 5beta-hydroxy steroid; alpha-L-rhamnoside; cardenolide glycoside; steroid hormone | anti-arrhythmia drug; cardiotonic drug; EC 2.3.3.1 [citrate (Si)-synthase] inhibitor; EC 3.1.3.41 (4-nitrophenylphosphatase) inhibitor; EC 3.6.3.10 (H(+)/K(+)-exchanging ATPase) inhibitor; EC 3.6.3.9 (Na(+)/K(+)-transporting ATPase) inhibitor; ion transport inhibitor; plant metabolite |
| digitoxin | digitoxin : A cardenolide glycoside in which the 3beta-hydroxy group of digitoxigenin carries a 2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1->4)-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1->4)-2,6-dideoxy-beta-D-ribo-hexopyranosyl trisaccharide chain. Digitoxin: A cardiac glycoside sometimes used in place of DIGOXIN. It has a longer half-life than digoxin; toxic effects, which are similar to those of digoxin, are longer lasting. (From Martindale, The Extra Pharmacopoeia, 30th ed, p665) | cardenolide glycoside | EC 3.6.3.9 (Na(+)/K(+)-transporting ATPase) inhibitor |
| digoxin | digoxin : A cardenolide glycoside that is digitoxin beta-hydroxylated at C-12. A cardiac glycoside extracted from the foxglove plant, Digitalis lanata, it is used to control ventricular rate in atrial fibrillation and in the management of congestive heart failure with atrial fibrillation, but the margin between toxic and therapeutic doses is small. Digoxin: A cardiotonic glycoside obtained mainly from Digitalis lanata; it consists of three sugars and the aglycone DIGOXIGENIN. Digoxin has positive inotropic and negative chronotropic activity. It is used to control ventricular rate in ATRIAL FIBRILLATION and in the management of congestive heart failure with atrial fibrillation. Its use in congestive heart failure and sinus rhythm is less certain. The margin between toxic and therapeutic doses is small. (From Martindale, The Extra Pharmacopoeia, 30th ed, p666) | cardenolide glycoside; steroid saponin | anti-arrhythmia drug; cardiotonic drug; EC 3.6.3.9 (Na(+)/K(+)-transporting ATPase) inhibitor; epitope |
| digitoxigenin | digitoxigenin : A 5beta-cardenolide that is 5beta-cardanolide with hydroxy substituents at the 3beta- and 14beta-positions and double bond unsaturation at C(20)-C(22). Digitoxigenin: 3 beta,14-Dihydroxy-5 beta-card-20(22)enolide. A cardenolide which is the aglycon of digitoxin. Synonyms: Cerberigenin; Echujetin; Evonogenin; Thevetigenin. | 14beta-hydroxy steroid; 3beta-hydroxy steroid | |
| phakellistatin 2 | phakellistatin 2: isolated from the marine sponge Phakellia carteri; structure in first source | ||
| digitoxigenin monodigitoxoside | digitoxigenin monodigitoxoside: RN given refers to (ribo-3beta,5beta)-isomer | ||
| evomonoside | evomonoside : A cardenolide glycoside consisting of digitoxigenin having an alpha-L-rhamnosyl moiety attached at the O(3)-position. evomonoside: a cytotoxic cardiac glycoside from Lepidium apetalum; RN refers to (3beta,5beta)-isomer | cardenolide glycoside | |
| halisulfate 1 | halisulfate 1: an isocitrate lyase inhibitor sesterterpene sulfate from sponge, Hippospongia sp.; structure in first source | organic molecular entity | metabolite |